Boceprevir (BPR)

Boceprevir is a protease inhibitor used as a treatment for hepatitis C genotype 1. It binds to HCV nonstructural 3 NS3 (HCV) active site. The SPRINT-1 trial was a phase II trial of boceprivir in difficult-to-treat patients with HCV genotype 1.The patients enrolled in the SPRINT-1 study were among the most difficult to treat, and were exclusively those with genotype 1.The SPRINT-2 trialwas a double-blind study which randomly assigned adults with untreated hepatitis C virus, genotype 1 to one of three groups. Each group received a month of peginterferon alfa-2b and ribavirin before being randomized to one of three arms. The RESPOND-2 trial studied patients with chronic hepatitis C genotype 1 who did not have a sustained response to therapy with peginterferon-ribavirin therapy. All patients received a month of peg-interferon alfa-2b and ribavirin before being randomized to one of three arms.